Value Investor
Start free

Ascendis Pharma A/S

ASND on Nasdaq. Pharmaceutical preparations. Market value $15.0bn.

Watch this stockFree. We tell you when something changes.

This company reports once a year (it is based outside the US), so every figure comes from its annual report for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Cash flow or capital spending isn't reported, so free cash flow is unknown.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
annual report to December 2025
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.

$226.05 a share, 21% above its 1-year low

Over the past year the price has ranged from $186.05 to $282.15.

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

n/a
n/a
n/a
n/a
n/a
20212022202320242025
Revenue
n/an/an/an/an/a
Operating margin
n/an/an/an/an/a
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.06bn0.06bn0.06bn0.06bn0.06bn

Health checks

  • Free cash flow positiveNot enough data
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Not enough data
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 9% more shares since 2021

Dates

Next results (estimated)
n/a
Last annual report (10-K)
11 February 2026
Next quarterly (estimated, 10-Q)
n/a

Who owns it

None of the long-term investors we follow own it. 311 funds in all.

Jun '25
Dec '25
Jun '26

Sold out this quarter

Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 2 insiders bought $777,068 of shares on the open market. 3 sold $6m.

  • Bodenhoff Mads
    SVP & PAO
    Sold
    Date
    8 September 2026
    Shares
    3,000
    Price
    $270.19
    Value
    $810,570
  • HOLTUG LARS
    Director
    Sold
    Date
    2 September 2026
    Shares
    236
    Price
    $264.13
    Value
    $62,335
  • BIENAIME JEAN JACQUES
    Director
    Bought
    Date
    14 August 2026
    Shares
    2,000
    Price
    $246.33
    Value
    $492,654
  • SMITH SCOTT THOMAS
    EVP & Chief Financial Officer
    Bought
    Date
    2 June 2026
    Shares
    100
    Price
    $219.00
    Value
    $21,900
  • BIENAIME JEAN JACQUES
    Director
    Bought
    Date
    29 May 2026
    Shares
    500
    Price
    $223.12
    Value
    $111,562
  • SMITH SCOTT THOMAS
    EVP & Chief Financial Officer
    Bought
    Date
    29 May 2026
    Shares
    250
    Price
    $223.32
    Value
    $55,830
  • BIENAIME JEAN JACQUES
    Director
    Bought
    Date
    26 May 2026
    Shares
    400
    Price
    $237.81
    Value
    $95,122
  • JENSEN FLEMMING STEEN
    See Remarks
    Sold
    Date
    11 May 2026
    Shares
    19,460
    Price
    $238.49
    Value
    $5m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

Ascendis Pharma A/S doesn’t file a US annual report (10-K), so we haven’t checked it.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.